Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) David Luci, President/CEO.

(6:57)

Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s interview with David Luci, President/CEO.

(5:37)

Biopharmaceutical – Acurx Pharmaceuticals, Inc.'s interview with David Luci, President/CEO

(4:31)

Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s interview with David Luci, President/CEO

(10:13)

Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s interview with David Luci, President/CEO.

(8:23)

Biopharmaceutical – Acurx Pharmaceuticals, Inc.'s interview with David Luci, President/CEO.

(6:27)

Acurx Pharmaceuticals (NASDAQ: ACXP)

(30:33)

A New Class of Antibiotics - Acurx Pharmaceuticals - David Luci

(9:1econd)

The Problem with Current Antibiotics - David Luci, CEO of Acurx Pharmaceuticals

(11:1econd)

Biopharmaceutical Formulation A Journey from Expression to Patient

(23:10)

Biopharmaceutical company says it expects to reach profitability in 2025

(3:5)

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)

(31:28)

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)

(28:3)

Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

(10:22)

ACXP Moved Up 34.95% Today

(27)

Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

(6:37)

Acurx Phamaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President / CEO.

(10:57)

Acurx Phamaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President / CEO

(6:43)

AcurX Pharmaceuticals Webcast Presentation @ Lytham Partners Spring 2022 Investor Conference

(34:26)